Dishman Carbogen Amcis Limited (NSE:DCAL)

India flag India · Delayed Price · Currency is INR
245.13
-1.80 (-0.73%)
Feb 7, 2025, 3:30 PM IST
26.45%
Market Cap 38.43B
Revenue (ttm) 26.19B
Net Income (ttm) -1.74B
Shares Out 156.78M
EPS (ttm) -11.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 258,775
Average Volume 483,931
Open 247.35
Previous Close 246.93
Day's Range 242.40 - 251.50
52-Week Range 133.00 - 307.98
Beta 1.33
RSI 50.97
Earnings Date Feb 7, 2025

About Dishman Carbogen Amcis

Dishman Carbogen Amcis Limited provides contract research and manufacturing services for the pharmaceutical, healthcare, and bio-technology industries worldwide. The company operates through Contract Research and Manufacturing Services and Marketable Molecules segments. It also manufactures and supplies bulk drugs, active pharmaceutical ingredients (APIs), and general and highly potent APIs; specialty chemicals comprising intermediates, fine chemicals, phosphoranes, solid quaternary ammonium compounds, wittig reagents, and various pharmaceutica... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1983
Employees 1,132
Stock Exchange National Stock Exchange of India
Ticker Symbol DCAL
Full Company Profile

Financial Performance

In 2023, Dishman Carbogen Amcis's revenue was 26.16 billion, an increase of 8.41% compared to the previous year's 24.13 billion. Losses were -1.53 billion, 414.9% more than in 2022.

Financial Statements

News

Dishman Carbogen subsidiary successfully completes Swissmedic inspection of its Vionnaz facility

CARBOGEN AMCIS AG, a subsidiary of Dishman Carbogen Amcis Limited, has announced the successful completion of a Swissmedic inspection at its Vionnaz facility in Switzerland. This achievement reaffirms...

4 weeks ago - Business Upturn